Clovis Oncology (CLVS) Misses Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. HNGE
10. SPY

Go back to Clovis Oncology (CLVS) Misses Q2 EPS by 5c

Clovis Oncology Announces Second Quarter 2021 Operating Results

August 4, 2021 8:00 AM EDT

$36.8M in Rubraca® (rucaparib) global net product revenues for Q2 2021, down 8% vs. Q2 2020, due to continuing impact of COVID-19 Phase 1/2 LuMIERE clinical study of FAP-2286 open for enrollment, first peptide-targeted radionuclide therapeutic candidate targeting FAP in clinical development Three top-line Phase 3 data read-outs for Rubraca anticipated over the next six to 18 months with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy $72.5M in net proceeds raised through at-the-market equity offering program in Q2 2021 $230.2M in cash and cash equivalents and... More